Gonorrhea Explained

Gonorrhea
Synonyms:Gonorrhoea, gonococcal infection, gonococcal urethritis, the clap
Field:Infectious disease
Symptoms:None, burning with urination, vaginal discharge, discharge from the penis, pelvic pain, testicular pain
Complications:Pelvic inflammatory disease, inflammation of the epididymis, septic arthritis, endocarditis
Causes:Neisseria gonorrhoeae typically sexually transmitted
Diagnosis:Testing the urine, urethra in males, or cervix in females
Prevention:Condoms, having sex with only one person who is uninfected, not having sex
Treatment:Ceftriaxone by injection and azithromycin by mouth
Frequency:0.8% (women), 0.6% (men)

Gonorrhoea or gonorrhea, colloquially known as the clap, is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Infection may involve the genitals, mouth, or rectum.[1] Infected men may experience pain or burning with urination, discharge from the penis, or testicular pain. Infected women may experience burning with urination, vaginal discharge, vaginal bleeding between periods, or pelvic pain. Complications in women include pelvic inflammatory disease and in men include inflammation of the epididymis. Many of those infected, however, have no symptoms. If untreated, gonorrhea can spread to joints or heart valves.

Gonorrhea is spread through sexual contact with an infected person. This includes oral, anal, and vaginal sex. It can also spread from a mother to a child during birth. Diagnosis is by testing the urine, urethra in males, or cervix in females.[2] Testing all women who are sexually active and less than 25 years of age each year as well as those with new sexual partners is recommended; the same recommendation applies in men who have sex with men (MSM).

Gonorrhea can be prevented with the use of condoms, having sex with only one person who is uninfected, and by not having sex.[2] [3] Treatment is usually with ceftriaxone by injection and azithromycin by mouth. Resistance has developed to many previously used antibiotics and higher doses of ceftriaxone are occasionally required.[4] [5] Retesting is recommended three months after treatment.[3] Sexual partners from the last two months should also be offered treatment.[2]

Gonorrhea affects about 0.8% of women and 0.6% of men.[6] An estimated 33 to 106 million new cases occur each year, out of the 498 million new cases of curable STI – which also includes syphilis, chlamydia, and trichomoniasis.[7] [8] Infections in women most commonly occur when they are young adults.[3] In 2015, it caused about 700 deaths.[9] Descriptions of the disease date back to before the Common Era within the Hebrew Bible/Old Testament (15:2-3 ).. The current name was first used by the Greek physician Galen before AD 200 who referred to it as "an unwanted discharge of semen".[10]

Signs and symptoms

Gonorrhea infections of mucosal membranes can cause swelling, itching, pain, and the formation of pus. The time from exposure to symptoms is usually between two and 14 days, with most symptoms appearing between four and six days after infection, if they appear at all. Both men and women with infections of the throat may experience a sore throat, though such infection does not produce symptoms in 90% of cases.[11] [12] Other symptoms may include swollen lymph nodes around the neck.[13] Either sex can become infected in the eyes or rectum if these tissues are exposed to the bacterium,[14] which can lead to pain with bowel movements, rectal discharge, or constipation.[15]

Women

Half of women with gonorrhea are asymptomatic but the other half experience vaginal discharge, lower abdominal pain, or pain with sexual intercourse associated with inflammation of the uterine cervix.[16] Common medical complications of untreated gonorrhea in women include pelvic inflammatory disease which can cause scars to the fallopian tubes and result in later ectopic pregnancy among those women who become pregnant.

Men

Most infected men with symptoms have inflammation of the penile urethra associated with a burning sensation during urination and discharge from the penis. In men, discharge with or without burning occurs in half of all cases and is the most common symptom of the infection.[17] This pain is caused by a narrowing and stiffening of the urethral lumen.[18] The most common medical complication of gonorrhea in men is inflammation of the epididymis.[19] Gonorrhea is also associated with increased risk of prostate cancer.[20]

Infants

If not treated, gonococcal ophthalmia neonatorum will develop in 28% of infants born to women with gonorrhea.[21]

Spread

If left untreated, gonorrhea can spread from the original site of infection and infect and damage the joints, skin, and other organs. Indications of this can include fever, skin rashes, sores, and joint pain and swelling.[19] In advanced cases, gonorrhea may cause a general feeling of tiredness similar to other infections.[22] [17] It is also possible for an individual to have an allergic reaction to the bacteria, in which case any appearing symptoms will be greatly intensified.[17] Very rarely it may settle in the heart, causing endocarditis, or in the spinal column, causing meningitis. Both are more likely among individuals with suppressed immune systems, however.[12]

Cause

Gonorrhea is caused by the bacterium Neisseria gonorrhoeae. Previous infection does not confer immunity – a person who has been infected can become infected again by exposure to someone who is infected. Infected persons may be able to infect others repeatedly without having any signs or symptoms of their own.[23]

Spread

The infection is usually spread from one person to another through vaginal, oral, or anal sex.[24] Men have a 20% risk of getting the infection from a single act of vaginal intercourse with an infected woman. The risk for men who have sex with men (MSM) is higher.[25] Insertive MSM may get a penile infection from anal intercourse, while receptive MSM may get anorectal gonorrhea. Women have a 60–80% risk of getting the infection from a single act of vaginal intercourse with an infected man.[26]

A mother may transmit gonorrhea to her newborn during childbirth; when affecting the infant's eyes, it is referred to as ophthalmia neonatorum. It may be able to spread through the objects contaminated with body fluid from an infected person.[27] The bacteria typically does not survive long outside the body, typically dying within minutes to hours.[28]

Risk factors

It is discovered that sexually active women younger than 25 and men who have sex with men are at increased risk of getting gonorrhea.[29]

Other risk factors include:

Complications

Untreated gonorrhea can lead to major complications, such as:

Diagnosis

Traditionally, gonorrhea was diagnosed with Gram stain and culture; however, newer polymerase chain reaction (PCR)-based testing methods are becoming more common.[31] [32] If initial treatment fails, a culture should be done to determine the sensitivity of the bacteria to antibiotics.

Tests that use PCR (aka nucleic acid amplification) to identify genes unique to N. gonorrhoeae are recommended for screening and diagnosis of gonorrhea infection. These PCR-based tests require a sample of urine, urethral swabs, or cervical/vaginal swabs. Culture (growing colonies of bacteria in order to isolate and identify them) and Gram-stain (staining of bacterial cell walls to reveal morphology) can also be used to detect the presence of N. gonorrhoeae in all specimen types except urine.[33] [34] Studies of the swab sample method for gonorrhea infections have not shown any difference in the number of patients treated, whether the sample was collected at home or in the clinic. The implications for number of patients cured, reinfection rates, partner management, and safety are unknown.[35]

If Gram-negative, oxidase-positive diplococci are visualized on direct Gram stain of urethral pus (male genital infection), no further testing is needed to establish the diagnosis of gonorrhea infection.[36] However, direct Gram stain of cervical swabs is not useful because the N. gonorrhoeae organisms are less concentrated in these samples. The chance of a false positive test is also higher for a cervical swab, as Gram-negative diplococci native to the normal vaginal flora cannot be distinguished from N. gonorrhoeae in that context. Thus, cervical swabs must be cultured under the conditions described above. If oxidase positive, Gram-negative diplococci are isolated from a culture of a cervical/vaginal swab specimen, then the diagnosis is made. Culture is especially useful for diagnosis of infections of the throat, rectum, eyes, blood, or joints—areas where PCR-based tests are not well established in all labs. Culture is also useful for antimicrobial sensitivity testing, analyzing treatment failure, and epidemiological purposes (outbreaks, surveillance).[37]

In patients who may have disseminated gonococcal infection (DGI), all possible mucosal sites should be cultured (e.g., pharynx, cervix, urethra, rectum).[38] Three sets of blood cultures should also be obtained. Synovial fluid should be collected in cases of septic arthritis.

All people testing positive for gonorrhea should be tested for other sexually transmitted infections such as chlamydia, syphilis, and human immunodeficiency virus.[39] Studies have found co-infection with chlamydia ranging from 46 to 54% in young people with gonorrhea.[40] [41] Among persons in the United States between 14 and 39 years of age, 46% of people with gonorrheal infection also have chlamydial infection.[42] For this reason, gonorrhea and chlamydia testing are often combined.[43] [44] People diagnosed with gonorrhea infection have a fivefold increase risk of HIV transmission.[45] Additionally, infected persons who are HIV positive are more likely to shed and transmit HIV to uninfected partners during an episode of gonorrhea.[46]

Screening

The United States Preventive Services Task Force (USPSTF) recommends screening for gonorrhea in women at increased risk of infection, which includes all sexually active women younger than 25 years. Extragenital gonorrhea and chlamydia are highest in men who have sex with men (MSM).[47] Additionally, the USPSTF also recommends routine screening in people who have previously tested positive for gonorrhea or have multiple sexual partners and individuals who use condoms inconsistently, provide sexual favors for money, or have sex while under the influence of alcohol or drugs.[16]

Screening for gonorrhea in women who are (or intend to become) pregnant, and who are found to be at high risk for sexually transmitted infections, is recommended as part of prenatal care in the United States.[48]

Prevention

As with most sexually transmitted infections, the risk of infection can be reduced significantly by the correct use of condoms, not having sex, or can be removed almost entirely by limiting sexual activities to a mutually monogamous relationship with an uninfected person.[49] [50]

Those previously infected are encouraged to return for follow up care to make sure that the infection has been eliminated. In addition to the use of phone contact, the use of email and text messaging have been found to improve the re-testing for infection.[51]

Newborn babies coming through the birth canal are given erythromycin ointment in the eyes to prevent blindness from infection. The underlying gonorrhea should be treated; if this is done then usually a good prognosis will follow.

Treatment

Antibiotics

Antibiotics are used to treat gonorrhea infections. As of 2016, both ceftriaxone by injection and azithromycin by mouth are most effective.[4] [52] [53] However, due to increasing rates of antibiotic resistance, local susceptibility patterns must be taken into account when deciding on treatment.[39] Ertapenem is a potential effective alternative treatment for ceftriaxone-resistant gonorrhea.[54] [55]

Adults may have eyes infected with gonorrhoea and require proper personal hygiene and medications.[56] Addition of topical antibiotics have not been shown to improve cure rates compared to oral antibiotics alone in treatment of eye infected gonorrhea.[57] For newborns, erythromycin ointment is recommended as a preventative measure for gonococcal infant conjunctivitis.[58]

Infections of the throat can be especially problematic, as antibiotics have difficulty becoming sufficiently concentrated there to destroy the bacteria. This is amplified by the fact that pharyngeal gonorrhoea is mostly asymptomatic, and gonococci and commensal Neisseria species can coexist for long time periods in the pharynx and share anti-microbial resistance genes. Accordingly, an enhanced focus on early detection (i.e., screening of high-risk populations, such as men who have sex with men, PCR testing should be considered) and appropriate treatment of pharyngeal gonorrhoea is important.[4]

Sexual partners

It is recommended that sexual partners be tested and potentially treated.[39] One option for treating sexual partners of people infected is patient-delivered partner therapy (PDPT), which involves providing prescriptions or medications to the person to take to his/her partner without the health care provider's first examining him/her.[59]

The United States' Centers for Disease Control and Prevention (CDC) currently recommend that individuals who have been diagnosed and treated for gonorrhea avoid sexual contact with others until at least one week past the final day of treatment in order to prevent the spread of the bacterium.[60]

Antibiotic resistance

See main article: Antibiotic resistance in gonorrhea. Many antibiotics that were once effective including penicillin, tetracycline, and fluoroquinolones are no longer recommended because of high rates of resistance.[39] Resistance to cefixime has reached a level such that it is no longer recommended as a first-line agent in the United States, and if it is used a person should be tested again after a week to determine whether the infection still persists.[61] Public health officials are concerned that an emerging pattern of resistance may predict a global epidemic.[62] [63] In 2016, the WHO published new guidelines for treatment, stating "There is an urgent need to update treatment recommendations for gonococcal infections to respond to changing antimicrobial resistance (AMR) patterns of N. gonorrhoeae. High-level resistance to previously recommended quinolones is widespread and decreased susceptibility to the extended-spectrum (third-generation) cephalosporins, another recommended first-line treatment in the 2003 guidelines, is increasing and several countries have reported treatment failures."[64]

Prognosis

Gonorrhea if left untreated may last for weeks or months with higher risks of complications. One of the complications of gonorrhea is systemic dissemination resulting in skin pustules or petechia, septic arthritis, meningitis, or endocarditis. This occurs in between 0.6 and 3% of infected women and 0.4 and 0.7% of infected men.

In men, inflammation of the epididymis, prostate gland, and urethra can result from untreated gonorrhea.[65] In women, the most common result of untreated gonorrhea is pelvic inflammatory disease. Other complications include inflammation of the tissue surrounding the liver,[65] a rare complication associated with Fitz-Hugh–Curtis syndrome; septic arthritis in the fingers, wrists, toes, and ankles; septic abortion; chorioamnionitis during pregnancy; neonatal or adult blindness from conjunctivitis; and infertility. Men who have had a gonorrhea infection have an increased risk of getting prostate cancer.[20]

Epidemiology

About 88 million cases of gonorrhea occur each year, out of the 448 million new cases of curable STI each year – that also includes syphilis, chlamydia and trichomoniasis.[8] The prevalence was highest in the African region, the Americas, and Western Pacific, and lowest in Europe.[66] In 2013, it caused about 3,200 deaths, up from 2,300 in 1990.[67]

In the United Kingdom, 196 per 100,000 males 20 to 24 years old and 133 per 100,000 females 16 to 19 years old were diagnosed in 2005.[68] In 2013, the CDC estimated that more than 820,000 people in the United States get a new gonorrheal infection each year. Fewer than half of these infections are reported to CDC. In 2011, 321,849 cases of gonorrhea were reported to the CDC. After the implementation of a national gonorrhea control program in the mid-1970s, the national gonorrhea rate declined from 1975 to 1997. After a small increase in 1998, the gonorrhea rate has decreased slightly since 1999. In 2004, the rate of reported gonorrheal infections was 113. 5 per 100,000 persons.[69]

In the US, it is the second-most-common bacterial sexually transmitted infections; chlamydia remains first.[70] [71] According to the CDC African Americans are most affected by gonorrhea, accounting for 69% of all gonorrhea cases in 2010.[72]

The World Health Organization warned in 2017 of the spread of untreatable strains of gonorrhea, following analysis of at least three cases in Japan, France and Spain, which survived all antibiotic treatment.[73]

History

Some scholars translate the biblical terms zav (for a male) and zavah (for a female) as gonorrhea.[74]

It has been suggested that mercury was used as a treatment for gonorrhea. Surgeons' tools on board the recovered English warship the Mary Rose included a syringe that, according to some, was used to inject the mercury via the urinary meatus into crewmen with gonorrhea. The name "the clap", in reference to the disease, is recorded as early as the sixteenth century, referring to a medieval red-light district in Paris, Les Clapiers. Translating to "The rabbit holes", it was so named for the small huts in which prostitutes worked.[75] [76]

Silver nitrate was one of the widely used drugs in the 19th century. However, it became replaced by Protargol. Arthur Eichengrün invented this type of colloidal silver, which was marketed by Bayer from 1897 onward. The silver-based treatment was used until the first antibiotics came into use in the 1940s.[77]

The exact time of onset of gonorrhea as prevalent disease or epidemic cannot be accurately determined from the historical record. One of the first reliable notations occurs in the Acts of the (English) Parliament. In 1161, this body passed a law to reduce the spread of "... the perilous infirmity of burning".[78] The symptoms described are consistent with, but not diagnostic of, gonorrhea. A similar decree was passed by Louis IX in France in 1256, replacing regulation with banishment.[79] Similar symptoms were noted at the siege of Acre by Crusaders.

Coincidental to, or dependent on, the appearance of a gonorrhea epidemic, several changes occurred in European medieval society. Cities hired public health doctors to treat affected patients without right of refusal. Pope Boniface rescinded the requirement that physicians complete studies for the lower orders of the Catholic priesthood.[80]

Medieval public health physicians in the employ of their cities were required to treat prostitutes infected with the "burning", as well as lepers and other epidemic patients.[81] After Pope Boniface completely secularized the practice of medicine, physicians were more willing to treat a sexually transmitted infection.[80]

Research

A vaccine for gonorrhea has been developed that is effective in mice.[82] It will not be available for human use until further studies have demonstrated that it is both safe and effective in the human population. Development of a vaccine has been complicated by the ongoing evolution of resistant strains and antigenic variation (the ability of N. gonorrhoeae to disguise itself with different surface markers to evade the immune system).

As N. gonorrhoeae is closely related to N. meningitidis and they have 80–90% homology in their genetic sequences some cross-protection by meningococcal vaccines is plausible. A study published in 2017 showed that MeNZB group B meningococcal vaccine provided a partial protection against gonorrhea.[83] The vaccine efficiency was calculated to be 31%.[84] In June 2023, GlaxoSmithKline won fast-track designation from the Food and Drug Administration for its vaccine candidate against gonorrhea.[85]

External links

Notes and References

  1. Book: Delong L, Burkhart N . General and Oral Pathology for the Dental Hygienist. 2017-11-27. Wolters Kluwer Health. 978-1-4963-5453-2. 787.
  2. Web site: Gonorrhea – CDC Fact Sheet (Detailed Version). CDC. 27 August 2016. 17 November 2015. live. https://web.archive.org/web/20160902004117/http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea-detailed.htm. 2 September 2016.
  3. Workowski KA, Bolan GA . Sexually transmitted diseases treatment guidelines, 2015 . MMWR. Recommendations and Reports . 64 . RR-03 . 1–137 . June 2015 . 26042815 . 5885289 .
  4. Web site: Antibiotic-Resistant Gonorrhea Basic Information. CDC. 27 August 2016. 13 June 2016. live. https://web.archive.org/web/20160908222601/http://www.cdc.gov/std/gonorrhea/arg/basic.htm. 8 September 2016.
  5. Unemo M . Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge . BMC Infectious Diseases . 15 . 364 . August 2015 . 26293005 . 4546108 . 10.1186/s12879-015-1029-2 . free .
  6. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, Stevens G, Gottlieb S, Kiarie J, Temmerman M . 6 . Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting . PLOS ONE . 10 . 12 . e0143304 . 8 December 2015 . 26646541 . 4672879 . 10.1371/journal.pone.0143304 . free . 2015PLoSO..1043304N .
  7. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, etal . Global Burden of Disease Study 2013 Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet . 386 . 9995 . 743–800 . August 2015 . 26063472 . 4561509 . 10.1016/s0140-6736(15)60692-4 .
  8. Emergence of multi-drug resistant Neisseria gonorrhoeae. World Health Organization. 2012. https://web.archive.org/web/20130613030128/http://whqlibdoc.who.int/hq/2011/WHO_RHR_11.14_eng.pdf. 13 June 2013. 2. dead.
  9. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1459–1544 . October 2016 . 27733281 . 5388903 . 10.1016/s0140-6736(16)31012-1 . Wang . Haidong . Naghavi . Mohsen . Allen . Christine . Barber . Ryan M. . Bhutta . Zulfiqar A. . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Zian . Coates . Matthew M. . Coggeshall . Megan . Dandona . Lalit . Dicker . Daniel J. . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Foreman . Kyle . Forouzanfar . Mohammad H. . Fraser . Maya S. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Huynh . Chantal . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kinfu . Yohannes . Kulikoff . Xie Rachel . 1 .
  10. Morgan MK, Decker CF . Gonorrhea . Disease-a-Month . 62 . 8 . 260–268 . August 2016 . 27107780 . 10.1016/j.disamonth.2016.03.009 .
  11. Zakher B, Cantor AG, Pappas M, Daeges M, Nelson HD . Screening for gonorrhea and Chlamydia: a systematic review for the U.S. Preventive Services Task Force . Annals of Internal Medicine . 161 . 12 . 884–893 . December 2014 . 25244000 . 10.7326/M14-1022 . 207538182 . 10.1.1.691.6232 .
  12. Book: Sexually Transmitted Diseases: A Physician Tells You What You Need to Know. Marr L . Second. 2007. 1998. Johns Hopkins University. Baltimore, Maryland. 978-0-8018-8658-4.
  13. Web site: Gonorrhea - Symptoms and causes. Mayo Clinic. en. 2019-08-06.
  14. Web site: 2022-04-05 . Detailed STD Facts - Gonorrhea . 2022-04-23 . www.cdc.gov . en-us.
  15. Keshvani . Neil . Gupta . Arjun . Incze . Michael A. . I Am Worried About Gonorrhea: What Do I Need to Know? . JAMA Internal Medicine . 1 January 2019 . 179 . 1 . 132 . 10.1001/jamainternmed.2018.4345 . 30398526 . free .
  16. Smith L, Angarone MP . Sexually Transmitted Infections . The Urologic Clinics of North America . 42 . 4 . 507–518 . November 2015 . 26475947 . 10.1016/j.ucl.2015.06.004 . 10.1.1.590.3827 . 37727850 .
  17. Book: Shmaefsky BR . Gonorrhea. 1 January 2009. Infobase. 978-1-4381-0142-2. 52.
  18. Book: Cheng L, Bostwick DG . Urologic Surgical Pathology E-Book. 24 January 2014. Elsevier Health Sciences. 978-0-323-08619-6. 863.
  19. Web site: What Complications Can Gonorrhea Cause?. WebMD. 2019.
  20. Caini S, Gandini S, Dudas M, Bremer V, Severi E, Gherasim A . Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis . Cancer Epidemiology . 38 . 4 . 329–338 . August 2014 . 24986642 . 10.1016/j.canep.2014.06.002 .
  21. Web site: Prophylaxis for Gonococcal and Chlamydial Ophthalmia Neonatorum in the Canadian Guide to Clinical Preventative Health Care. Public Health Agency of Canada. dead. https://web.archive.org/web/20100310075359/http://www.phac-aspc.gc.ca//publicat/clinic-clinique/pdf/s1c16e.pdf. 10 March 2010.
  22. Web site: Complications from gonorrhea . 2022-04-25 . stanfordhealthcare.org . en.
  23. Web site: Gonorrhea - Symptoms and causes . 2022-04-23 . Mayo Clinic . en.
  24. Trebach JD, Chaulk CP, Page KR, Tuddenham S, Ghanem KG . Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures . Sexually Transmitted Diseases . 42 . 5 . 233–239 . May 2015 . 25868133 . 4672628 . 10.1097/OLQ.0000000000000248 .
  25. Howard Brown Health Center: STI Annual Report, 2009
  26. National Institute of Allergy and Infectious Diseases; National Institutes of Health, Department of Health and Human Services (20 July 2001). "Workshop Summary: Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention". Hyatt Dulles Airport, Herndon, Virginia. pp14
  27. Goodyear-Smith F . What is the evidence for non-sexual transmission of gonorrhoea in children after the neonatal period? A systematic review . Journal of Forensic and Legal Medicine . 14 . 8 . 489–502 . November 2007 . 17961874 . 10.1016/j.jflm.2007.04.001 .
  28. Book: Shmaefsky BR . Gonorrhea. 1 January 2009. Infobase. 978-1-4381-0142-2. 48.
  29. Book: Holmes KK . Sexually transmitted diseases . 1984 . McGraw-Hill . 644578106.
  30. May 2013 . A Randomized, Controlled Trial of inSPOT and Patient-Delivered Partner Therapy for Gonorrhea and Chlamydial Infection Among Men Who Have Sex With Men . Sexually Transmitted Diseases . 40 . 5 . 432 . 10.1097/olq.0b013e31829349ec . 0148-5717. free .
  31. Ljubin-Sternak S, Meštrović T . Chlamydia trachomatis and Genital Mycoplasmas: Pathogens with an Impact on Human Reproductive Health . Journal of Pathogens . 2014 . 183167 . 183167 . 2014 . 25614838 . 4295611 . 10.1155/2014/183167 . free .
  32. Barry PM, Klausner JD . The use of cephalosporins for gonorrhea: the impending problem of resistance . Expert Opinion on Pharmacotherapy . 10 . 4 . 555–577 . March 2009 . 19284360 . 2657229 . 10.1517/14656560902731993 .
  33. Web site: Final Recommendation Statement: Chlamydia and Gonorrhea: Screening – US Preventive Services Task Force. uspreventiveservicestaskforce.org. en. 2017-12-07.
  34. Web site: Gonococcal Infections – 2015 STD Treatment Guidelines. cdc.gov. en-us. 2017-12-07.
  35. Fajardo-Bernal L, Aponte-Gonzalez J, Vigil P, Angel-Müller E, Rincon C, Gaitán HG, Low N . Home-based versus clinic-based specimen collection in the management of Chlamydia trachomatis and Neisseria gonorrhoeae infections . The Cochrane Database of Systematic Reviews . 2015 . 9 . CD011317 . September 2015 . 26418128 . 8666088 . 10.1002/14651858.CD011317.pub2 . Cochrane STI Group .
  36. Book: Review of medical microbiology and immunology. Levinson W . 9780071818117. Thirteenth . New York. 871305336. 2014-07-01.
  37. Ng LK, Martin IE . The laboratory diagnosis of Neisseria gonorrhoeae . The Canadian Journal of Infectious Diseases & Medical Microbiology . 16 . 1 . 15–25 . January 2005 . 18159523 . 2095009 . 10.1155/2005/323082 . free .
  38. https://www.cdc.gov/std/tg2015/clinical.htm section on prevention methods
  39. Deguchi T, Nakane K, Yasuda M, Maeda S . Emergence and spread of drug resistant Neisseria gonorrhoeae . The Journal of Urology . 184 . 3 . 851–8; quiz 1235 . September 2010 . 20643433 . 10.1016/j.juro.2010.04.078 .
  40. Kahn RH, Mosure DJ, Blank S, Kent CK, Chow JM, Boudov MR, Brock J, Tulloch S . 6 . Chlamydia trachomatis and Neisseria gonorrhoeae prevalence and coinfection in adolescents entering selected US juvenile detention centers, 1997-2002 . Sexually Transmitted Diseases . 32 . 4 . 255–259 . April 2005 . 15788927 . 10.1097/01.olq.0000158496.00315.04 . 20864079 . free .
  41. Dicker LW, Mosure DJ, Berman SM, Levine WC . Gonorrhea prevalence and coinfection with chlamydia in women in the United States, 2000 . Sexually Transmitted Diseases . 30 . 5 . 472–476 . May 2003 . 12916141 . 10.1097/00007435-200305000-00016 . 39361152 . free .
  42. Datta SD, Sternberg M, Johnson RE, Berman S, Papp JR, McQuillan G, Weinstock H . Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002 . Annals of Internal Medicine . 147 . 2 . 89–96 . July 2007 . 17638719 . 10.7326/0003-4819-147-2-200707170-00007 . 16507728 .
  43. Web site: Gonococcal Infections - 2015 STD Treatment Guidelines. 2018-01-04.
  44. Book: Ryan KJ, Ray CG . Sherris Medical Microbiology . 4th . McGraw Hill . 2004 . 978-0-8385-8529-0 .
  45. Web site: Emergence of multi-drug resistant Neisseria gonorrhoeae – Threat of global rise in untreatable sexually transmitted infections. Department of Reproductive Health and Research. 2011. FactSheet WHO/RHR/11.14. World Health Organization.
  46. Web site: Gonorrhea – STD information from CDC. 2017-10-06. cdc.gov. en-us. 2017-12-05.
  47. Meyers D, Wolff T, Gregory K, Marion L, Moyer V, Nelson H, Petitti D, Sawaya GF . 6 . USPSTF recommendations for STI screening . American Family Physician . 77 . 6 . 819–824 . March 2008 . 18386598 .
  48. http://www.icsi.org/prenatal_care_4/prenatal_care__routine__full_version__2.html Health Care Guideline: Routine Prenatal Care. Fourteenth Edition.
  49. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004526/ section: Prevention
  50. https://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm section: How can gonorrhea be prevented?
  51. Desai M, Woodhall SC, Nardone A, Burns F, Mercey D, Gilson R . Active recall to increase HIV and STI testing: a systematic review . Sexually Transmitted Infections . 91 . 5 . 314–323 . August 2015 . 25759476 . 10.1136/sextrans-2014-051930 . free .
  52. Web site: Antibiotic-resistant gonorrhoea on the rise, new drugs needed. World Health Organization. 10 July 2017. 7 July 2017. live. https://web.archive.org/web/20170709050132/http://www.who.int/mediacentre/news/releases/2017/Antibiotic-resistant-gonorrhoea/en/. 9 July 2017.
  53. Sánchez-Busó L, Golparian D, Corander J, Grad YH, Ohnishi M, Flemming R, Parkhill J, Bentley SD, Unemo M, Harris SR . 6 . The impact of antimicrobials on gonococcal evolution . Nature Microbiology . 4 . 11 . 1941–1950 . November 2019 . 31358980 . 6817357 . 10.1038/s41564-019-0501-y .
  54. de Vries HJ, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, de Korne-Elenbaas J, van Dam AP, Schim van der Loeff MF . 6 . Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial . The Lancet. Infectious Diseases . 22 . 5 . 706–717 . May 2022 . 35065063 . 10.1016/S1473-3099(21)00625-3 . 246129045 .
  55. Web site: Antibiotic Ertapenem is alternative drug in treatment of gonorrhea . Amsterdam UMC . 8 July 2022 . 20 January 2022.
  56. Sadowska-Przytocka A, Czarnecka-Operacz M, Jenerowicz D, Grzybowski A . Ocular manifestations of infectious skin diseases . Clinics in Dermatology . 34 . 2 . 124–128 . 2016 . 26903179 . 10.1016/j.clindermatol.2015.11.010 .
  57. Epling J . Bacterial conjunctivitis . BMJ Clinical Evidence . 2012 . February 2012 . 22348418 . 3635545 .
  58. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB . 6 . Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: US Preventive Services Task Force Reaffirmation Recommendation Statement . JAMA . 321 . 4 . 394–398 . January 2019 . 30694327 . 10.1001/jama.2018.21367 . free .
  59. https://www.cdc.gov/std/treatment/EPTFinalReport2006.pdf "Expedited partner therapy in the management of sexually transmitted diseases"
  60. Web site: Gonorrhea – CDC Fact Sheet. U.S. Centers for Disease Control and Prevention . 17 October 2014. 14 July 2014. live. https://web.archive.org/web/20161216052928/http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm. 16 December 2016.
  61. Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections . MMWR. Morbidity and Mortality Weekly Report . 61 . 31 . 590–594 . August 2012 . 22874837 . Centers for Disease Control Prevention (CDC) .
  62. Sex and the Superbug . The New Yorker . 2012-10-01 . Groopman J . LXXXVIII . 30 . 26–31 . 2012-10-13 . ...public-health experts [see]...the emergence of a strain of gonorrhea that is resistant to the last drug available against it, and the harbinger of a sexually transmitted global epidemic. . live . https://web.archive.org/web/20121009062727/http://www.newyorker.com/reporting/2012/10/01/121001fa_fact_groopman . 9 October 2012.
  63. Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, Heidler S, Unemo M . 6 . Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022 . Euro Surveillance . 27 . 24 . June 2022 . 35713023 . 9205165 . 10.2807/1560-7917.ES.2022.27.24.2200455 . 249747652 .
  64. Web site: WHO guidelines for the treatment of Neisseria gonorrhoeae . World Health Organization . 2016 . 24 September 2020 .
  65. Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; & Mitchell, Richard N. (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. pp. 705–706
  66. Kirkcaldy RD, Weston E, Segurado AC, Hughes G . Epidemiology of gonorrhoea: a global perspective . Sexual Health . 16 . 5 . 401–411 . September 2019 . 31505159 . 7064409 . 10.1071/SH19061 . .
  67. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 . Lancet . 385 . 9963 . 117–171 . January 2015 . 25530442 . 4340604 . 10.1016/s0140-6736(14)61682-2.
  68. Moran JS . Gonorrhoea . BMJ Clinical Evidence . 2007 . March 2007 . 19454057 . 2943790 .
  69. Web site: Gonorrhea – CDC Fact Sheet. CDC. 29 May 2012. 2013-12-20. live. https://web.archive.org/web/20161216052928/http://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea.htm. 16 December 2016.
  70. Web site: CDC – STD Surveillance – Gonorrhea. 2008-08-21 . https://web.archive.org/web/20080306085420/http://www.cdc.gov/std/stats/gonorrhea.htm . 2008-03-06.
  71. Web site: CDC Fact Sheet – Chlamydia. 2008-08-21. live. https://web.archive.org/web/20161216052855/http://www.cdc.gov/std/chlamydia/stdfact-chlamydia.htm. 16 December 2016.
  72. Web site: STD Trends in the United States: 2010 National Data for Gonorrhea, Chlamydia, and Syphilis. Centers for Disease Control and Prevention (CDC). 22 November 2010. live. https://web.archive.org/web/20120124104622/http://www.cdc.gov/std/stats10/tables/trends-table.htm. 24 January 2012.
  73. News: Untreatable gonorrhoea 'superbug' spreading around world, WHO warns. The Daily Telegraph. 7 July 2017. live. https://web.archive.org/web/20170707065204/https://www.theguardian.com/society/2017/jul/07/untreatable-gonorrhoea-superbug-spreading-around-world-who-warns. 7 July 2017.
  74. Web site: Daf Parashat Hashavua . 2012-11-02 . live . https://web.archive.org/web/20121003062653/http://www.biu.ac.il/JH/Parasha/eng/metzora/nitzan.html . 3 October 2012.
  75. Book: The Mirror for Magistrates . 1587 . Higgins J . The Mirror for Magistrates . as cited in the Oxford English Dictionary entry for "clap".
  76. Baarda BI, Sikora AE . Proteomics of Neisseria gonorrhoeae: the treasure hunt for countermeasures against an old disease . Frontiers in Microbiology . 6 . 1190 . 2015 . 26579097 . 4620152 . 10.3389/fmicb.2015.01190 . free .
  77. Bender M . Ueber neuere Antigonorrhoica (insbes. Argonin und Protargol). Archives of Dermatological Research. 1898. 43. 1. 31–36. 10.1007/BF01986890. 45492365.
  78. Book: Sanger W . History of Prostitution . New York . Harper . 1910 .
  79. Book: LaCroix P . The History of Prostitution . 2 . New Yory . MacMillan . 1931 .
  80. Book: Moen J, Bivens L . Basic Healthcare Studies: Sexually Transmitted Disease. Alpha Editions . 2017. 9789386367570.
  81. Book: Leiky WE . History of European Morals . New York . MacMillan . 1926 .
  82. Jerse AE, Bash MC, Russell MW . Vaccines against gonorrhea: current status and future challenges . Vaccine . 32 . 14 . 1579–1587 . March 2014 . 24016806 . 4682887 . 10.1016/j.vaccine.2013.08.067 .
  83. Gottlieb SL, Johnston C . Future prospects for new vaccines against sexually transmitted infections . Current Opinion in Infectious Diseases . 30 . 1 . 77–86 . February 2017 . 27922851 . 5325242 . 10.1097/QCO.0000000000000343 .
  84. Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S . Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study . Lancet . 390 . 10102 . 1603–1610 . September 2017 . 28705462 . 10.1016/S0140-6736(17)31449-6 . 4230156 .
  85. News: 27 June 2023. GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation. Reuters. 20 August 2023.